GCP
XGN icon

GSA Capital Partners’s Exagen XGN Stock Holding History

GSA Capital Partners’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$998K Sell
214,721
-38,284
-15% -$144K 0.06% 503
2026
Q1 		$759K Buy
253,005
+218,459
+632% +$845K 0.05% 628
2025
Q4 		$210K Buy
+34,546
New +$314K 0.02% 1385
2025
Q2 		– Sell
-12,287
Closed -$44K – 2205
2025
Q1 		$44K Buy
+12,287
New +$46.4K ﹤0.01% 1557

Other funds holding XGN

WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

GSA Capital Partners's XGN Position: Q2 2026 in Review

GSA Capital Partners reduced its Exagen (XGN) stake by 15% in Q2 2026, selling an estimated $144K and leaving 214,721 shares worth $998K. The position accounts for 0.06% of the portfolio, ranked #503.

GSA Capital Partners first reported a position in XGN in Q1 2025 and has held it in 4 quarters since. 57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

  • GSA Capital Partners held 214,721 shares of Exagen worth $998K as of Q2 2026.
  • GSA Capital Partners sold 38,284 Exagen shares in Q2 2026, an estimated $144K.
  • Exagen made up 0.06% of GSA Capital Partners's portfolio in Q2 2026, its #503 holding.
  • GSA Capital Partners first reported a position in Exagen in Q1 2025 and has held it in 4 quarters since.
  • 57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.